Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Myeloma
•
Hematology
Does the presence of osteoporosis change the extent of workup that should be performed for an older patient with otherwise serologically low-risk MGUS?
Would your considerations change for a man v. a woman?
Related Questions
How do you modify Daratumumab-RVD relative to the protocols used in trials when used as a first-line agent to transplant-eligible patients with myeloma?
What are alternative myeloma therapies for patients who are unable to afford lenalidomide or oral cyclophosphamide due to gaps in prescription drug coverage?
How do you discuss harms of MGUS screening with other medical providers?
What induction regimen do you choose for high risk newly diagnosed multiple myeloma in light of the recent high risk focused studies?
How would you approach a patient with solitary plasmacytoma with an FLC ratio >100, but a negative bone marrow biopsy and negative PET-CT?
What post-auto maintenance therapy do you recommend for patients with high-risk multiple myeloma?
Is a bone marrow biopsy necessary in a patient with a previous tissue diagnosis of plasmacytoma or smoldering multiple myeloma, who now meets criteria for active myeloma?
What is your approach to vaccinations and titers for patients with myeloma, who are immunosuppressed and do not have appropriate antibody responses to vaccines?
How would you approach choosing a regimen for a patient with multiple myeloma refractory to daratumumab and lenalidomide, with severe neuropathy from bortezomib?
How is monoclonal gammopathy of renal significance (MGRS) different from myeloma kidney?